CLINUVEL PHARMACEUTICALS LIMITED Clinuvel Pharmaceuticals Limited Share Price Deutsche Boerse AG
Equities
UR9
AU000000CUV3
Pharmaceuticals
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.538 EUR | +0.40% |
|
+3.49% | -2.91% |
| Sales 2024 * | 88.33M 58.74M 54.98M 4.65B | Sales 2025 * | 96.39M 64.11M 60M 5.08B | Capitalization | 770M 512M 479M 40.58B |
|---|---|---|---|---|---|
| Net income 2024 * | 34M 22.61M 21.17M 1.79B | Net income 2025 * | 36M 23.94M 22.41M 1.9B | EV / Sales 2024 * | 6.61 x |
| Net cash position 2024 * | 187M 124M 116M 9.83B | Net cash position 2025 * | 219M 146M 136M 11.55B | EV / Sales 2025 * | 5.72 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
21.2
x | Employees | - |
| Yield 2024 * |
0.43% | Yield 2025 * |
0.47% | Free-Float | 79.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Clinuvel Pharmaceuticals Limited
More press releases
More news
| 1 day | +0.40% | ||
| 1 week | +3.49% | ||
| Current month | +0.16% | ||
| 1 month | +1.10% | ||
| 3 months | +15.00% | ||
| 6 months | -0.67% | ||
| Current year | -2.91% |
1 week
9.25
9.67
1 month
8.829.67
Current year
7.9010.05
1 year
7.9012.68
3 years
7.9027.00
5 years
6.8527.00
10 years
0.9427.00
| Managers | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 31/10/05 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 31/10/05 |
Lachlan Hay
COO | Chief Operating Officer | - | 31/12/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 31/10/05 |
| Director/Board Member | - | 05/02/07 | |
Karen Agersborg
BRD | Director/Board Member | - | 28/01/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/24 | 9.635 | +1.42% | 154 |
| 25/06/24 | 9.5 | +1.06% | 8,300 |
| 24/06/24 | 9.4 | +0.16% | 1,200 |
| 21/06/24 | 9.385 | +1.40% | 0 |
| 20/06/24 | 9.255 | -0.59% | 480 |
Delayed Quote Deutsche Boerse AG, June 26, 2024 at 01:40 pm
More quotes
Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Companyâs pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.38
AUD
Average target price
26.79
AUD
Spread / Average Target
+74.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.87% | 94.22B | |
| -4.08% | 37.76B | |
| -13.92% | 32.5B | |
| +73.38% | 27.75B | |
| -11.50% | 16.13B | |
| -1.72% | 14.19B | |
| -11.67% | 11.42B | |
| +190.36% | 11.06B | |
| -52.61% | 9.09B |
- Stock Market
- Equities
- CUV Stock
- UR9 Stock
